| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
61,660,000 |
| Market
Cap: |
47.61(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6394 - $5.82 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile AlloVir is a late clinical-stage cell therapy company developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. Co.'s Pipeline includes: Posoloeucel, which is an allogeneic, off-the-shelf virus-specific T cell (VST) therapy candidate targeting adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus that can lead to devastating viral disease in the allogeneic hematopoietic cell transplant population; and ALVR106, which is an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by human metapneumovirus, influenza, parainfluenza virus and respiratory syncytial virus.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
2,930,870 |
2,930,870 |
| Total Buy Value |
$0 |
$0 |
$10,990,763 |
$10,990,763 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
49,511 |
191,640 |
263,030 |
1,586,782 |
| Total Sell Value |
$37,495 |
$144,338 |
$351,679 |
$10,312,191 |
| Total People Sold |
4 |
4 |
4 |
7 |
| Total Sell Transactions |
20 |
38 |
59 |
108 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Atillasoy Ercem |
See Remarks |
• – – |
2022-10-20 |
4 |
S |
$8.48 |
$12,956 |
D/D |
(1,527) |
131,372 |
|
30% |
|
| Sinha Vikas |
See Remarks |
• • • |
2022-10-19 |
4 |
S |
$9.36 |
$13,564 |
D/D |
(1,449) |
1,036,775 |
|
36% |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2022-10-19 |
4 |
S |
$9.36 |
$10,016 |
D/D |
(1,070) |
399,800 |
|
36% |
|
| Miller Edward |
General Counsel |
• – – |
2022-10-19 |
4 |
S |
$9.36 |
$5,176 |
D/D |
(553) |
249,377 |
|
36% |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2022-10-19 |
4 |
AS |
$9.36 |
$3,229 |
D/D |
(345) |
113,233 |
|
-36% |
|
| Atillasoy Ercem |
See Remarks |
• – – |
2022-10-19 |
4 |
S |
$9.36 |
$5,317 |
D/D |
(568) |
132,899 |
|
36% |
|
| Hallal David |
Director |
– • • |
2022-10-19 |
4 |
S |
$8.45 |
$5,070,000 |
I/I |
(600,000) |
138,153 |
|
36% |
|
| Hallal David |
Director |
– • • |
2022-09-29 |
4 |
S |
$7.35 |
$2,940,920 |
I/I |
(400,000) |
720,965 |
|
21% |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2022-09-02 |
4 |
S |
$7.89 |
$3,889 |
D/D |
(493) |
400,870 |
|
26% |
|
| Brainard Diana |
Chief Executive Officer |
• • – |
2022-08-18 |
4 |
S |
$7.76 |
$35,429 |
D/D |
(4,564) |
637,548 |
|
35% |
|
| Sinha Vikas |
See Remarks |
• • – |
2022-08-16 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
1,038,224 |
|
- |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2022-08-16 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
401,363 |
|
- |
|
| Van Beek Jeroen B |
Chief Commercial Officer |
• – – |
2022-08-16 |
4 |
S |
$8.30 |
$129,473 |
D/D |
(15,590) |
386,363 |
|
43% |
|
| Miller Edward |
General Counsel |
• – – |
2022-08-16 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
249,930 |
|
- |
|
| Brainard Diana |
Chief Executive Officer |
• • – |
2022-08-16 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
642,112 |
|
- |
|
| Leen Ann M. |
Chief Scientific Officer |
• – – |
2022-08-16 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
43,000 |
|
- |
|
| Hagen Brett R |
Chief Accounting Officer |
• – – |
2022-08-16 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
113,578 |
|
- |
|
| Gilead Sciences Inc |
10% Owner |
– – • |
2022-07-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
13,704,416 |
|
46% |
|
| Globeways Holdings Ii Ltd |
Director |
– • • |
2022-07-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,768,207 |
|
46% |
|
| Globeways Holdings Ii Ltd |
Director |
– • • |
2022-07-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,059,884 |
|
46% |
|
| Elevatebio, Llc |
Director |
– • • |
2022-07-28 |
4 |
A |
$4.61 |
$15,000,000 |
D/D |
3,253,796 |
16,674,766 |
|
- |
|
| Sinha Vikas |
See Remarks |
• • • |
2022-07-28 |
4 |
A |
$4.61 |
$15,000,000 |
I/I |
3,253,796 |
16,674,766 |
|
- |
|
| Hallal David |
Director |
– • • |
2022-07-28 |
4 |
A |
$4.61 |
$15,000,000 |
I/I |
3,253,796 |
16,674,766 |
|
- |
|
| Gadicke Ansbert |
Director |
– • • |
2022-07-28 |
4 |
A |
$4.61 |
$15,000,000 |
I/I |
3,253,796 |
16,674,766 |
|
- |
|
| Jovan-Embiricos Morana |
Director |
– • • |
2022-07-28 |
4 |
A |
$4.61 |
$37,581,859 |
I/I |
8,152,247 |
16,674,766 |
|
- |
|
288 Records found
|
|
Page 5 of 12 |
|
|
0.02 (2.93%) 
